Effects of folic acid combined with vitamin B12 on DVT in patients with homocysteine cerebral infarction

What Was Tested

The paper reports a study of Cyanocobalamin (Vitamin B12), published as a randomized controlled trial.

To investigate the effects of folic acid combined with vitamin B12 on deep vein thrombosis (DVT) in patients with homocysteine cerebral infarction.

Who Took Part

The study group was 90 patients.

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

90 patients with homocysteine cerebral infarction with DVT that were admitted to their hospital from January to July 2015 were selected as study subjects.

They were divided into 2 groups randomly, the treatment group (n=45) and the non-treatment group (n=45).

How the Study Was Run

In design terms this was a randomized study.

The patients were allocated by chance, so the Cyanocobalamin (Vitamin B12) group and the comparison group should start out alike.

The treatment group was administered folic acid and vitamin B12, while the non-treatment group wasn't administered folic acid and vitamin B12.

The researchers compared and analyzed the levels of Hcy, folic acid and vitamin B12 of both groups.

The researchers investigated the correlation between the groups of patients with Hcy and folic acid and vitamin B12 treatment.

The researchers performed a comparative analysis of both groups of patients with an anticoagulant international normalized ratio (INR).

The INR was recorded in detail for the first time as standard time, stable value time, obtain stable INR value time, activated partial thromboplastin time (APTT) and Prothrombin Time (PT) by color Doppler ultrasound observation of both groups with recurrent thrombosis.

What Was Measured

PubMed files the paper under topics including Cerebral Infarction, Folic Acid, Homocysteine, International Normalized Ratio, Recurrence, Venous Thrombosis and Vitamin B 12.

What This Means in Plain Language

The paper is a randomized study of Cyanocobalamin (Vitamin B12) in 90 patients.

Its findings take up roughly 10 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2017 (European review for medical and pharmacological sciences), a journal based in United States.

More context: the Cyanocobalamin (Vitamin B12) compound page, all human trials.